You made it through the first year. You lost weight. The nausea calmed down. The dose held steady. And then someone asked you the question everyone asks: what happens in year two?
A new analysis from Epic Research published in August looked at 25,213 adults without diabetes who stayed on semaglutide or tirzepatide continuously for at least a year, lost at least 5 pounds during that first year, and kept going. The question was simple. Did they maintain what they lost, did they keep losing, or did they regain?
At the two year mark, 53% of semaglutide patients were maintaining the weight they had reached after year one. Another 31.9% had lost even more. Put together, about 85% were either maintaining or continuing to lose.
The tirzepatide numbers were stronger. Just over half, 52.9%, were maintaining their year one weight, while another 39.3% were still losing. That means roughly 92% had either maintained or extended their original weight loss.
Regain happened, but not the way most people fear
Some patients did regain weight during year two. By the end of the second year, 14.9% of semaglutide patients had regained at least one quarter of the weight they lost during the first year. For tirzepatide, it was about 8%.
Full regain, back to the starting weight, was uncommon.
There is one important limitation. The study only followed people who continued treatment. Anyone who went more than 60 days without a prescription was no longer counted. So these results tell us what happened among people who stayed on their medication, not everyone who ever started one.
Why this matters if you haven’t started yet: If you are starting, know this: the patients who stayed on treatment mostly kept their weight off or kept losing. The problem is not year two. The problem is stopping.
What happens if you switch from an injection to a pill
A separate randomized phase 3B trial called Attain Maintain, led by Dr. Louis Aronne of Weill Cornell Medicine and published in Nature Medicine, tested a different question. What happens if you lose a substantial amount of weight on an injection and then switch to the daily oral GLP-1 orforglipron, made by Lilly?
The study looked at people who had already lost significant weight on injectable semaglutide or tirzepatide and then switched them to either orforglipron or placebo.
Among former semaglutide patients, those switched to orforglipron maintained 79% of their previous weight loss compared with 37.6% on placebo. Among former tirzepatide patients, those switched to orforglipron maintained 75% compared with 49% on placebo.
There was more regain among the people coming off tirzepatide, which makes sense when you look at how the drugs work. Tirzepatide activates both GIP and GLP-1 receptors, while orforglipron only works on GLP-1.
Novo is testing whether patients really need the full Wegovy dose
For years, the GLP-1 dosing conversation has mostly gone in one direction: start low, move up slowly, and eventually reach the recommended maintenance dose. Novo Nordisk is now formally testing the opposite question. How much Wegovy do patients really need once the medication is working?
Novo has started a new phase 3 trial called Oasis 5. The study began in August and will enroll about 450 adults with obesity or overweight plus at least one weight related health condition who do not have diabetes. Researchers will test two lower maintenance doses of the Wegovy pill against placebo over 60 weeks.
Novo has not disclosed exactly which lower doses it is studying. The currently approved long term dose of the Wegovy pill is 25 milligrams once a day. The pill is also available in 1.5, 4 and 9 milligram strengths as patients work their way up.
Novo already knows the 25 milligram dose works. In the phase 3 Oasis trial led by obesity specialist Dr. Sean Wharton and published in the New England Journal of Medicine, at 64 weeks the semaglutide pill group lost about 14% of their body weight on average compared with about 2% with placebo. More than a third, about 34%, lost at least 20% of their starting body weight compared with just 3% on placebo.
So Novo already knows the 25 milligram dose works. It wants to know whether some patients can get enough benefit with less.
People are using low dosages of these products. They just decide on their own.DOWNSIZED
The lower dose pills are already seeing strong demand
There is a very practical reason Novo is asking this question. The company says the lower dose Wegovy tablets are already seeing particularly strong demand among cash paying patients, and those lower strengths have been priced at roughly half the cost of the higher doses in the United States.
Patients are not necessarily waiting for a clinical trial before making those decisions. Novo CEO Lars Fruergaard Jørgensen told Reuters that people are lowering their dose on their own, some because of side effects, some because of cost, some because they are in maintenance and simply feel they do not need as much medication anymore.
Novo told Reuters that having more maintenance dose options could give doctors and patients greater flexibility. The Wegovy pill only launched earlier this year and it already produced about 500 million dollars in second quarter sales.
This trial does not answer that question yet. Oasis 5 has just begun. There are no results and it is expected to run into 2028. What has changed is that Novo Nordisk is now spending the money and running a phase 3 trial to answer a question patients have been asking for years. After all of the attention paid to how high people should go, we are finally going to get good data on how low some patients may be able to stay.
Novo has a mystery new weight loss drug in testing
Patients ask constantly what is coming behind cagrilintide and amycretin in Novo's pipeline. There is another candidate now, and almost nothing about it is public.
The drug is called NNC0721-8060. Novo has registered a phase 1 first in human trial that plans to enroll 142 adults between 18 and 55 with a BMI between 27 and 34.9. The early part of the study focuses on safety and a later portion will start measuring change in body weight.
One detail stands out. Novo is including semaglutide as an active comparator alongside placebo. That tells us the company wants this measured against the molecule behind Wegovy from the start.
Beyond that, we do not know much. Novo has not identified the target, the mechanism, or even the type of molecule. And there is no published preclinical paper explaining how it works. The trial registration is essentially the only public look at it right now.
There is no human efficacy data, no weight loss percentage, and nothing yet that separates NNC0721-8060 from any other phase 1 drug. But Novo already has semaglutide, cagrilintide and amycretin in development. The trial runs into 2027, so we will start learning what this actually is over the next year.
The next GLP-1 breakthrough may be fewer side effects, not more weight loss
For the last few years, obesity drugs have mostly competed on one number: how much weight people lose. Now the competition is shifting. Companies are trying to build drugs that can deliver strong weight loss with fewer side effects, especially nausea, vomiting, diarrhea and constipation.
One of the biggest areas of interest is amylin, a hormone that helps regulate fullness and blood sugar but works through a different pathway than GLP-1.
One drug getting attention is petrelintide, being developed by Zealand Pharma and Roche. In a phase 2 study, petrelintide produced about 10.7% average weight loss and the gastrointestinal side effect rates were reported much closer to placebo than what we usually see with GLP-1s. That weight loss is lower than what we have seen with tirzepatide, but the tolerability profile is exactly why researchers are watching it. Petrelintide has now moved into phase 3 testing.
Novo Nordisk is taking another approach with cagrilintide, which combines semaglutide with the amylin analog cagrilintide. In phase 3, cagrilintide has produced weight loss in the low 20 percents. Novo is also developing amycretin, a drug that activates both GLP-1 and amylin pathways. Early studies have shown weight loss around 20% at some doses.
If a new medication produces about the same weight loss as Zepbound but causes more nausea, it is going to be difficult to justify. If it produces a little less weight loss but is much easier to stay on, that could still be a very attractive option for a lot of patients.
The next generation of obesity drugs is not just trying to push the average weight loss number higher. It is trying to make treatment easier to live with.
Why this matters if you haven’t started yet: Turns out you cannot lose weight on a drug you cannot tolerate and stay on.
A Colorado biotech is developing an exercise pill for weight regain
A Colorado biotech company is developing a daily pill based on a chemical signal our bodies naturally produce during intense exercise, and the company now has its first human data.
The drug is called ENV-308 and it is being developed by Invida. This week the company reported results from a phase 1 study involving 88 healthy adult volunteers. The trial was designed to test safety, tolerability and how the drug behaves in the body, not whether it causes weight loss.
ENV-308 is designed to mimic lac-phe, short for lactate phenylalanine. Lac-phe is a small molecule that rises sharply after high intensity exercise and has been linked in early research to appetite regulation and metabolism. Invida has taken that biology and engineered an oral drug that can remain active much longer than naturally occurring lac-phe.
Invida founder and CEO Viswanath Devaraj described the idea this way: ENV-308 is our attempt to put the chemistry of exercise into a daily tablet. That is a great line, but it needs some context. This is not exercise in a pill. Nobody has shown that ENV-308 can reproduce the cardiovascular, muscular or metabolic benefits of actually exercising. What the company is trying to copy is one specific chemical signal produced during exercise.
The phase 1 safety results are encouraging. Invida reported no serious adverse events, no treatment discontinuations and no dose interruptions across the 88 volunteers, with relatively few gastrointestinal side effects. That last point is especially interesting because nausea, vomiting, diarrhea and constipation are among the most common reasons people struggle with current GLP-1 medications.
Researchers also saw a reduction in circulating leptin, a hormone involved in appetite and energy regulation. Invida believes that could be an early sign that the drug is reaching the metabolic biology it was designed to affect. But it is still an exploratory finding and does not prove that ENV-308 will produce meaningful weight loss in people.
The more ambitious claims come from animal studies. Invida says ENV-308 helped preserve lean muscle during weight loss and reduced weight regain after weight loss treatment was stopped. These results have not yet been demonstrated in humans.
The next study targets people who stopped GLP-1s
Invida plans to move ENV-308 into phase 2 and specifically study people who have stopped or are planning to stop GLP-1 treatment. The company wants to know whether a daily pill could help people maintain the weight they lost without continuing a GLP-1 indefinitely.
That is a very different goal from trying to beat Zepbound or Retatrutide on weight loss. ENV-308 is being developed as a possible maintenance therapy after GLP-1 treatment, with a different mechanism and, if the early safety profile holds up, potentially fewer gastrointestinal side effects.
We are still very early on this one. There is no human weight loss result yet, no evidence that the drug prevents regain in people, and no guarantee it will survive phase 2. But the science is unusual enough to watch closely. Take one of the chemical signals generated during exercise, turn it into a daily pill, and see whether it can help people hold on to the metabolic benefit and weight loss they achieved with GLP-1s.
Notice what all of these studies have in common. They are not racing to see who can hit 30% weight loss first. They are asking whether patients can stay on lower doses, whether switching to a pill helps people maintain, whether a new mechanism can reduce nausea, and whether a maintenance drug could prevent regain after stopping.
The next generation of GLP-1 science is not just about losing more weight. It is about making it possible to stay on treatment long enough to keep it off.
Questions people ask
What happens after 2 years on semaglutide or tirzepatide?
In a study of 25,213 patients who stayed on treatment, about 85% of semaglutide patients and 92% of tirzepatide patients either maintained their year one weight loss or continued losing more. Full regain back to starting weight was uncommon.
Can you switch from a GLP-1 injection to a pill and maintain weight loss?
A phase 3B trial found that patients who switched from injectable semaglutide or tirzepatide to the oral GLP-1 orforglipron maintained 75 to 79% of their previous weight loss, compared with 37 to 49% on placebo. There was more regain among patients coming off tirzepatide.
Is Novo Nordisk testing lower doses of Wegovy for maintenance?
Yes. Novo has started a phase 3 trial called Oasis 5 testing two lower maintenance doses of the Wegovy pill against placebo over 60 weeks in 450 adults. The company has not disclosed which doses, but the trial is expected to run into 2028.
Christopher and Lorraine Durham started tirzepatide in September 2023 and have lost over 150 pounds together. They read studies, earnings calls and fine print for their YouTube audience of GLP-1 patients. 124,716 views on the original video.
Watch the original on YouTube →